DavidWilliamBrandesMD

Neurology • Knoxville, TN

Past Assistant Clinical Professor of Neurology, UCLA; Hope MS Center, Knoxville, TN

Join to view full profile

Dr. Brandes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brandes' full profile

Already have an account?

Office
2060 Lakeside Centre Way
Knoxville, TN 37922
Phone+1 865-218-6222

Fax+1 865-218-6220

Summary

David W. Brandes, MS, MD, FAAN, FASA, received his master’s degree in biochemistry and his medical degree from the University of California, Los Angeles (UCLA) and VA Wadsworth Hospital, West Los Angeles. He also completed his internship and neurology residency training at UCLA. In 1972-73, he was the first Multiple Sclerosis (MS) Fellow in the United States, a position sponsored by the National MS Society. He was an Assistant Clinical Professor at UCLA until moving to Knoxville, TN in 2008. He has served as a Clinical Instructor at South College in Knoxville, TN, since 2013.
Dr. Brandes is a board-certified neurologist and has been elected as a Fellow of the American Academy of Neurology, as well as a Fellow of the American Stroke Association. He is also an MS Certified Specialist by the Consortium of MS Centers. In 1977 he started his neurology private practice in Northridge, California, a suburb of Los Angeles, where he was the founder of the Northridge Neurological Center. In 1996, he was the founder/Director of the Northridge Multiple Sclerosis Center where he cared for over 1000 active patients with MS. In 2008 he moved to Knoxville, TN, where he currently practices at the Hope Neurology/MS Center with about 2000 active MS patients
In California he was also the Director of the Northridge Hospital Sleep Evaluation Center and Rest Analysis, a sleep disorders center in Garden Grove, California.
Dr. Brandes has been involved in a variety of MS research projects including immunosuppressive treatment, cerebrospinal fluid analysis, glatiramer acetate studies, beta-interferon studies, sleep disorders in MS and medication adherence. He lectures throughout the United States, as well as internationally, about the treatment of multiple sclerosis. He has authored 25 articles about multiple sclerosis research and treatment in peer-reviewed medical journals.
Dr. Brandes previously served on the Board of Directors and the Chapter Program

Education & Training

VA Greater Los Angeles Healthcare SystemResidency, Neurology, 1972 - 1976
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Allergy and Immunology, 1972 - 1973
VA Greater Los Angeles Healthcare SystemInternship, Transitional Year, 1971 - 1972
David Geffen School of Medicine at UCLAClass of 1971
University of California at Los AngelesMS, Biochemistry, 1965 - 1968
Knox CollegeAB, Chemistry, 1964 - 1965
Knox CollegeBachelors, 1961 - 1963
University of IllinoisBachelors, Dentistry, 1963

Certifications & Licensure

CA State Medical License 1972 - 2025
TN State Medical License 2009 - 2025
TX State Medical License 2023 - 2024
MD State Medical License 1974 - 1988
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly
Fellow American Academy of Neurology
Top Doctor Award

Publications & Presentations

PubMed

30 citations
Redefining functionality and treatment efficacy in multiple sclerosis.
John Foley, David W. Brandes
Neurology. 2009-06-09
212 citations
Factors that influence adherence with disease-modifying therapy in MS.
Katherine Treadaway, Gary Cutter, Amber Salter, Sharon G. Lynch, James Simsarian
Journal of Neurology. 2009-04-27
71 citations
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
Neetu Agashivala, Ning Wu, Safiya Abouzaid, You Wu, Edward Kim
BMC Neurology. 2013-10-04

Journal Articles

Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis
Brandes, DW, Raimundo, K, Agashivala, N and Kim, E, Journal of Medical Economics, 1/1/2013
A Cross-sectional Survey of Patient Satisfaction and Subjective Experiences of Treatment With Fingolimod
Hanson KA, Agashivala N, Stringer SM, Balantac Z, Brandes DW, Patient Preference and Adherence, 1/1/2013
Compliance to Fingolimod and Other Disease Modifying Treatments in Multiple Sclerosis Patients, A Retrospective Cohort Study
Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW, BMC Neurology, 1/1/2013
Hidden Disabilities in Multiple Sclerosis—The Impact of Multiple Sclerosison Patients and Their Caregivers
Giovannoni, G, Foley, JF and Brandes, DW, European Neurological Review, 1/1/2012
The Manifold Economic Impact of Multiple Sclerosis--Indirect and Direct Costs of Managing Patients
Brandes, DW and Rieckmann, P, European Neurological Review, 1/1/2012
Managing Adverse Effects of Disease-modifying Agents Used for Treatment of Multiple Sclerosis
Moses H Jr, Brandes DW, Curr Med Res Opin, 9/1/2008
Alleviating Flu-like Symptoms with Dose Titration and Analgesics in MS Patients on Intramuscular Interferon Beta-1a Therapy: a Pilot Study
Brandes, DW, Bigley, K, Hornstein W, Cohen, H, Au W, Shubin R, Curr Med Res Opin, 7/1/2007
Quantification of De Novo Central Nervous System IgG Measles Antibody Synthesis in SSPE
Tourtellotte, W.W.; Ma, B.I.; Brandes, D.W.; Walsh, M.J.; Potvin, A.R., Ann Neurol, 1/1/1981
Join now to see all

Abstracts/Posters

Treatment Selection in Multiple Sclerosis: Results of a Physician Survey
Hanson, KA, Agashivala, N, Raimundo, K, Kim, E, Stringer, SM, Balantac, Z, Wyrwich, KW, Brandes, DW, Consortium of MS Centers, Orlando, FL, 5/31/2013
Impact of Real World Adherence on Effectiveness of First-line DMT's in Multiple Sclerosis
Agashivala, N, Raimundo, K, Kim, E, Brandes, DW, American Academy of Neurology Annual Meeting, San Diego, CA, 3/18/2013
Comparison of Compliance to Fingolimod and Other First-Line Disease Modifying Treatments Among Patients with Multiple Sclerosis
Abouzaid, S, Wu, N, Wu, Y, Kim, E, Boulanger, L, Brandes, DW, Academy of Managed Care Pharmacy, Cincinnati, OH, 10/7/2012
Alleviating Flu-like Symptoms with Dose Titration and Analgesics in MS Patients on Intramuscular Interferon Beta-1a Therapy: a Pilot Study
Brandes, DW, Bigley, K, Hornstein W, Cohen, H, Au W, Shubin R, Consortium of MS Centers, 1/1/2006
Brain and Measles-Specific Immunoglobulin-G in Cerebrospinal Fluid of Patients with Subacute Sclerosing Panencephalitis
Ma, B.I.; Tourtellotte, W.W., Brandes, D.W., Neurology, 1/1/1976
A Method to Estimate the Synthesis of Immunoglobulin-G inside the Blood-Brain Barrier in Multiple Sclerosis
Murthy, K.N., Fleming, J.O., Levy, J., Brandes, D.W., Tourtellotte, W.W., Neurology, 1/1/1976
Quantitation of Measles and Brain Specific IgG in Subacute Sclerosing Panencephalitis (SSPE), Cerebrospinal Fluid (CSF)
Ma, B.I.; Tourtellotte, W.W.; Brandes, D.W.; Sever, J.L., Fed. Proc, 1/1/1976
Schemes to Eradicate the Multiple Sclerosis Central Nervous System Immune Reaction
Tourtellotte, W.W.; Murthy, K.; Brandes, D.W.; Sjaben, N.; Ma, B.I. ; Somiso, P.; Potvin,A.; Costanza, A.; Korelitz, J., Neurology, 1/1/1976
Immunosuppressive Therapy of Multiple Sclerosis: I. Further Studies with X-irradiation of Central Nervous System
Tourtellotte, W.W., Murthy, K.N., Brandes, D.W., Jurkowitz, J., Fleming, J.O., Neurology, 1/1/1975
Cerebrospinal Fluid (CSF) Immunoglobulin-G (IgG) of Extravascular Origin in Normals and Patients with Multiple Sclerosis (MS)
Tourtellotte, W.W., Haerer, A.F., Fleming, J.O., Murthy, K.N., Levy, J., Brandes, D.W., Clinical Correlations, Trans. Am. Neurol. Assoc., 1/1/1975
Join now to see all

Lectures

Sleepless Nights
4/29/1995
Fatigue and Sleep Disorders in Multiple Sclerosis in Symptom Management in MS
3/16/2013
Sleep Disorders in Multiple Sclerosis
1/1/2013
Comparison of Time to Discontinuation Among Multiple Sclerosis Patients Receiving Fingolimod and Other First-Line Disease Modifying Treatments
Lyon, France - 10/11/2012
Innovative Treatment and Management of Multiple Sclerosis 2001
Riverside, CA - 1/27/2001
Post-Traumatic Head Syndrome
Encino, CA - 10/1/2000
MS...Moving Forward
Oxnard, CA - 9/9/2000
Symptomatic Treatment in Multiple Sclerosis
Victoria, BC, Canada - 7/23/2000
Multiple Sclerosis; New Advances, Clinical Round Table
West Los Angeles, CA - 6/13/2000
MS Research Update
Sherman Oaks, CA - 5/20/2000
New Approaches to the Treatment of Common and Uncommon Sleep Disorders
Northridge Hospital Medical Center, Northridge, CA - 5/17/2000
Multiple Sclerosis - New Treatment and Management Strategies
Bakersfield, CA - 5/6/2000
Taking the Next Steps
Northridge, CA - 4/26/2000
Neurological Assessment
Northridge, CA - 3/23/2000
Evaluation of Altered Mental Status
Northridge, CA - 11/24/1999
New Dimensions in MS Treatment
Santa Maria, CA - 10/30/1999
Innovative Treatment and Management of MS: New Medical and Rehabilitative Strategies
Santa Maria, CA - 10/19/1999
Challenges in the Clinical Management of MS and ECTRIMS/ACTRIMS Update
Baja California, Mexico - 9/26/1999
Newly Diagnosed Multiple Sclerosis Forum
Long Beach, CA - 4/24/1999
Controversies in Multiple Sclerosis Treatment
Edmunton, Alberta, Canada - 4/12/1999
Multiple Sclerosis Therapeutic Update
Alta, UT - 3/28/1999
Use of 4-Aminopyridine in Multiple Sclerosis
Alta, UT - 2/26/1999
Migraine Management: From First Line to Rescue Therapy
Westlake Village, CA - 10/8/1998
Multiple Sclerosis Symptomatic Treatment
Kaiser Hospital, Bellflower, CA - 8/13/1998
Understanding MS: An Educational Program for People Who Are Newly Diagnosed
6/22/1998
Join now to see all

Other

Say Goodnight to Sleep Disorders in Multiple Sclerosis
Brandes, DW, MSFocus
1/1/2013
Multiple Sclerosis Radio Talk Show
Brandes, DW, Colin Fluxman Show
Oxnard, CA - 2/18/2000
Sleep Disorders Radio Talk Show
Brandes, DW, Colin Fluxman Show
Oxnard, CA - 1/29/2000